-
Something wrong with this record ?
Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer
M. Gómez-Herranz, J. Faktor, M. Yébenes Mayordomo, M. Pilch, M. Nekulova, L. Hernychova, KL. Ball, B. Vojtesek, TR. Hupp, S. Kote
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
BB/C511599/1
Biotechnology and Biological Sciences Research Council - United Kingdom
NLK
Directory of Open Access Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
PubMed
36008984
DOI
10.3390/biom12081090
Knihovny.cz E-resources
- MeSH
- Antigens, Differentiation metabolism MeSH
- HLA-B Antigens * metabolism MeSH
- Humans MeSH
- Membrane Proteins genetics metabolism MeSH
- RNA, Messenger genetics MeSH
- Uterine Cervical Neoplasms * genetics MeSH
- RNA-Binding Proteins genetics metabolism MeSH
- Serine-Arginine Splicing Factors genetics MeSH
- RNA Splicing Factors MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The IFITM restriction factors play a role in cancer cell progression through undefined mechanisms. We investigate new protein-protein interactions for IFITM1/3 in the context of cancer that would shed some light on how IFITM1/3 attenuate the expression of targeted proteins such as HLA-B. SBP-tagged IFITM1 protein was used to identify an association of IFITM1 protein with the SRSF1 splicing factor and transporter of mRNA to the ribosome. Using in situ proximity ligation assays, we confirmed a predominant cytosolic protein-protein association for SRSF1 and IFITM1/3. Accordingly, IFITM1/3 interacted with HLA-B mRNA in response to IFNγ stimulation using RNA-protein proximity ligation assays. In addition, RT-qPCR assays in IFITM1/IFITM3 null cells and wt-SiHa cells indicated that HLA-B gene expression at the mRNA level does not account for lowered HLA-B protein synthesis in response to IFNγ. Complementary, shotgun RNA sequencing did not show major transcript differences between IFITM1/IFITM3 null cells and wt-SiHa cells. Furthermore, ribosome profiling using sucrose gradient sedimentation identified a reduction in 80S ribosomal fraction an IFITM1/IFITM3 null cells compared to wild type. It was partially reverted by IFITM1/3 complementation. Our data link IFITM1/3 proteins to HLA-B mRNA and SRSF1 and, all together, our results begin to elucidate how IFITM1/3 catalyze the synthesis of target proteins. IFITMs are widely studied for their role in inhibiting viruses, and multiple studies have associated IFITMs with cancer progression. Our study has identified new proteins associated with IFITMs which support their role in mediating protein expression; a pivotal function that is highly relevant for viral infection and cancer progression. Our results suggest that IFITM1/3 affect the expression of targeted proteins; among them, we identified HLA-B. Changes in HLA-B expression could impact the presentation and recognition of oncogenic antigens on the cell surface by cytotoxic T cells and, ultimately, limit tumor cell eradication. In addition, the role of IFITMs in mediating protein abundance is relevant, as it has the potential for regulating the expression of viral and oncogenic proteins.
Institute of Genetics and Cancer University of Edinburgh Edinburgh EH4 2XU UK
International Centre for Cancer Vaccine Science University of Gdańsk 80 822 Gdańsk Poland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024886
- 003
- CZ-PrNML
- 005
- 20221031100602.0
- 007
- ta
- 008
- 221017s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biom12081090 $2 doi
- 035 __
- $a (PubMed)36008984
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Gómez-Herranz, Maria $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $1 https://orcid.org/000000020403609X
- 245 10
- $a Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer / $c M. Gómez-Herranz, J. Faktor, M. Yébenes Mayordomo, M. Pilch, M. Nekulova, L. Hernychova, KL. Ball, B. Vojtesek, TR. Hupp, S. Kote
- 520 9_
- $a The IFITM restriction factors play a role in cancer cell progression through undefined mechanisms. We investigate new protein-protein interactions for IFITM1/3 in the context of cancer that would shed some light on how IFITM1/3 attenuate the expression of targeted proteins such as HLA-B. SBP-tagged IFITM1 protein was used to identify an association of IFITM1 protein with the SRSF1 splicing factor and transporter of mRNA to the ribosome. Using in situ proximity ligation assays, we confirmed a predominant cytosolic protein-protein association for SRSF1 and IFITM1/3. Accordingly, IFITM1/3 interacted with HLA-B mRNA in response to IFNγ stimulation using RNA-protein proximity ligation assays. In addition, RT-qPCR assays in IFITM1/IFITM3 null cells and wt-SiHa cells indicated that HLA-B gene expression at the mRNA level does not account for lowered HLA-B protein synthesis in response to IFNγ. Complementary, shotgun RNA sequencing did not show major transcript differences between IFITM1/IFITM3 null cells and wt-SiHa cells. Furthermore, ribosome profiling using sucrose gradient sedimentation identified a reduction in 80S ribosomal fraction an IFITM1/IFITM3 null cells compared to wild type. It was partially reverted by IFITM1/3 complementation. Our data link IFITM1/3 proteins to HLA-B mRNA and SRSF1 and, all together, our results begin to elucidate how IFITM1/3 catalyze the synthesis of target proteins. IFITMs are widely studied for their role in inhibiting viruses, and multiple studies have associated IFITMs with cancer progression. Our study has identified new proteins associated with IFITMs which support their role in mediating protein expression; a pivotal function that is highly relevant for viral infection and cancer progression. Our results suggest that IFITM1/3 affect the expression of targeted proteins; among them, we identified HLA-B. Changes in HLA-B expression could impact the presentation and recognition of oncogenic antigens on the cell surface by cytotoxic T cells and, ultimately, limit tumor cell eradication. In addition, the role of IFITMs in mediating protein abundance is relevant, as it has the potential for regulating the expression of viral and oncogenic proteins.
- 650 _2
- $a diferenciační antigeny $x metabolismus $7 D000943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a HLA-B antigeny $x metabolismus $7 D015235
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a membránové proteiny $x genetika $x metabolismus $7 D008565
- 650 _2
- $a sestřihové faktory $7 D000072260
- 650 _2
- $a messenger RNA $x genetika $7 D012333
- 650 _2
- $a proteiny vázající RNA $x genetika $x metabolismus $7 D016601
- 650 _2
- $a serin-arginin sestřihové faktory $x genetika $7 D000068103
- 650 12
- $a nádory děložního čípku $x genetika $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Faktor, Jakub $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic
- 700 1_
- $a Yébenes Mayordomo, Marcos $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $1 https://orcid.org/0000000156738440
- 700 1_
- $a Pilch, Magdalena $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland
- 700 1_
- $a Nekulova, Marta $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000164042566
- 700 1_
- $a Hernychova, Lenka $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic
- 700 1_
- $a Ball, Kathryn L $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK
- 700 1_
- $a Vojtesek, Borivoj $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000161943705
- 700 1_
- $a Hupp, Ted R $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000303910352
- 700 1_
- $a Kote, Sachin $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland
- 773 0_
- $w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 12, č. 8 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36008984 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100600 $b ABA008
- 999 __
- $a ok $b bmc $g 1854543 $s 1176176
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 8 $e 20220808 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
- GRA __
- $a BB/C511599/1 $p Biotechnology and Biological Sciences Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20221017